To determine the efficacy of PTGES2 and RNASET2 for BCC across a broad spectrum of human diseases, we conducted MR-PheWAS analysis on 2,408 phenotypes from the FinnGen R10 study. This evidence concerns the gene RNASET2 and skin basal cell carcinoma.